Pfizer and BioNTech – who have said they can prepare a new, Omicron-targeted version of Comirnaty within a matter of weeks if necessary – released new data this morning that it says showed a ...

According to Pfizer/BioNTech, preclinical data has shown that a booster dose with the BA.4/BA.5-adapted bivalent vaccine generated a strong neutralising antibody response against Omicron BA.1, BA ...

Pfizer and BioNTech have started clinical trials of a new Covid vaccine which targets the Omicron variant. The companies plan to test the protection gained from the new vaccine as a booster jab ...

Stacker consulted research from Yale Medical School and the World Health Organization to find how SARS-CoV-2 has evolved ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Following the EC decision, Pfizer and BioNTech’s Omicron KP.2-adapted COVID-19 vaccine will ship to European Union (EU) member states that have specifically ordered this formulation. The CHMP ...

Both Moderna and Pfizer-BioNTech manufacture the COVID vaccine in lower doses ... but they're not immune to the virus. "At ...

Non-clinical data showed better response compared to the Omicron XBB.1.5-adapted vaccine. The Health Sciences Authority has ...

Hong Kong will have another choice for a Covid-19 vaccine targeting the Omicron variant, with drug maker BioNTech offering to make its second-generation jabs available in the city as early as ...

On July 3, 2024, BioNTech and Pfizer’s Omicron JN.1-adapted COVID-19 vaccine was approved by the European Commission (“EC”). Shortly following approval, the updated vaccines were made available to ...

Opinions expressed by Forbes Contributors are their own. Dave Wessner is a virologist who covers infectious diseases. In the continuing effort to mitigate the effects of Covid-19, the U.S. Food ...

A new variant of COVID called XEC — a combination of two Omicron subvariants — is spreading in the middle of flu season.